Lecigon

Levodopa/Carbidopa/Entacapone, the active ingredient in Lecigon, is a combination antiparkinson agent presented as an oral tablet for oral administration. It is indicated for the management of Parkinson's disease, helping to reduce motor fluctuations and improve daily functioning in affected patients.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company provides reliable sourcing, documentation support, and timely delivery to meet the needs of healthcare providers.

Lecigon, a combination antiparkinson agent, is used in the management of Parkinson's disease and related motor complications.

- Parkinson's disease (early to moderate): improves overall motor symptoms and daily functioning. - Parkinson's disease with motor fluctuations: reduces OFF time and prolongs ON periods. - Advanced Parkinson's disease with wearing‑off: enhances the duration of levodopa action and stabilizes response.

Lecigon may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dyskinesia: involuntary movements, especially at higher doses. - Orthostatic hypotension: dizziness upon standing. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and rigidity. - Severe hepatic impairment: rare liver enzyme elevations. - Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Lecigon, clinicians should consider several safety precautions to minimize risk. - Cardiovascular monitoring: assess blood pressure and heart rate due to possible hypotension. - Psychiatric evaluation: monitor for hallucinations, confusion, or impulse control disorders. - Renal function: adjust use in patients with severe renal impairment. - Hepatic function: evaluate liver enzymes before initiating therapy. - Concomitant MAO‑B inhibitors: avoid co‑administration to prevent hypertensive crisis. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lecigon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis. - Anticholinergic agents: can exacerbate cognitive side effects. - CNS depressants (e.g., opioids, benzodiazepines): increase risk of sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Iron supplements or antacids: reduce levodopa absorption; separate dosing by at least 2 hours. - Diuretics (e.g., thiazides): may enhance orthostatic hypotension.